Christopher Benz

Christopher Benz

UNVERIFIED PROFILE

Are you Christopher Benz?   Register this Author

Register author
Christopher Benz

Christopher Benz

Publications by authors named "Christopher Benz"

Are you Christopher Benz?   Register this Author

99Publications

-Reads

Discovery of internalizing antibodies to basal breast cancer cells.

Protein Eng Des Sel 2018 Jan;31(1):17-28

Department of Anesthesia and Perioperative Care, University of California, San Francisco Rm 3C-38, Zuckerberg San Francisco General Hospital and Trauma Center, 1001 Potrero Ave, San Francisco, CA 94110, USA.

View Article
January 2018

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

Breast Cancer Res Treat 2017 Nov 4;166(2):593-601. Epub 2017 Aug 4.

Department of Biosciences and Nutrition, Karolinska Institutet, Hälsovägen 7, 141 83, Stockholm, Sweden.

View Article
November 2017

Functional IGF1R variant predicts breast cancer risk in women with preeclampsia in California Teachers Study.

Cancer Causes Control 2017 Oct 18;28(10):1027-1032. Epub 2017 Aug 18.

Buck Institute for Research on Aging, Novato, CA, USA.

View Article
October 2017

Comment on: 'Hypertensive diseases in pregnancy and breast cancer risk'.

Br J Cancer 2016 05 3;114(11):e10. Epub 2016 May 3.

Child Health and Development Studies of the Public Health Institute, Berkeley, CA 94709, USA.

View Article
May 2016

Targeting Molecular Aberrations in Breast Cancer: Is It about Time?

Am Soc Clin Oncol Educ Book 2012 :186-91

From the Carol Franc Buck Breast Care Center, University of California, San Francisco; Cancer and Developmental Therapeutics Program, Buck Institute for Research on Aging, Novato, CA; Breast Cancer Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

View Article
April 2016

FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index.

Breast Cancer Res Treat 2015 Nov 12;154(1):23-32. Epub 2015 Oct 12.

Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA, 94945, USA.

View Article
November 2015

DGCR8 is essential for tumor progression following PTEN loss in the prostate.

EMBO Rep 2015 Sep 23;16(9):1219-32. Epub 2015 Jul 23.

The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California - San Francisco, San Francisco, CA, USA Center for Reproductive Sciences, University of California - San Francisco, San Francisco, CA, USA Department of Urology, University of California - San Francisco, San Francisco, CA, USA Department of Anatomic Pathology, University of California - San Francisco, San Francisco, CA, USA.

View Article
September 2015

Sources of superoxide/H2O2 during mitochondrial proline oxidation.

Redox Biol 2014 18;2:901-9. Epub 2014 Jul 18.

Buck Institute for Research on Aging, Novato, CA 94945, USA.

View Article
April 2015

A steroid metabolizing gene variant in a polyfactorial model improves risk prediction in a high incidence breast cancer population.

BBA Clin 2014 Dec 8;2:94-102. Epub 2014 Nov 8.

Division of Hematology-Oncology, University of California, San Francisco, CA, USA ; Buck Institute for Research on Aging, Novato, CA, USA.

View Article
December 2014

First pregnancy events and future breast density: modification by age at first pregnancy and specific VEGF and IGF1R gene variants.

Cancer Causes Control 2014 Jul 7;25(7):859-68. Epub 2014 May 7.

Marin County Department of Health and Human Services, 899 Northgate Drive, Suite 415, San Rafael, CA, 94903, USA,

View Article
July 2014

RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth.

Oncotarget 2014 Jul;5(13):5165-76

Buck Institute for Research on Aging; Novato, CA, USA. Oncology-Hematology Division, Department of Medicine, University of California, San Francisco, CA USA.

View Article
July 2014

Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma.

Mol Cell Proteomics 2014 Apr 6;13(4):1034-49. Epub 2014 Feb 6.

Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, California 94945;

View Article
April 2014

mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.

Breast Cancer Res Treat 2014 Apr 22;144(2):287-298. Epub 2014 Feb 22.

Buck Institute for Research on Aging, 8001 Redwood Boulevard, Novato, CA 94945, USA,

View Article
April 2014

FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.

Breast Cancer Res Treat 2013 Jun 28;139(2):381-90. Epub 2013 May 28.

Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.

View Article
June 2013

Age-related micro-RNA abundance in individual C. elegans.

Aging (Albany NY) 2013 Jun;5(6):394-411

Buck Institute for Research on Aging, 8001 Redwood Boulevard, Novato, CA 94945, USA.

View Article
June 2013

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.

Breast Cancer Res 2010 14;12(5):R85. Epub 2010 Oct 14.

Buck Institute for Age Research, Novato, CA 94945, USA.

View Article
February 2013

PARADIGM-SHIFT predicts the function of mutations in multiple cancers using pathway impact analysis.

Bioinformatics 2012 Sep;28(18):i640-i646

Department of Biomolecular Engineering and CBSE, University of California Santa Cruz, Santa Cruz, CA 95064, USA.

View Article
September 2012

Biologic markers determine both the risk and the timing of recurrence in breast cancer.

Breast Cancer Res Treat 2011 Sep 20;129(2):607-16. Epub 2011 May 20.

Department of Surgery and Radiology, University of California, San Francisco, CA 94115, USA.

View Article
September 2011

Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers.

Breast Cancer Res Treat 2011 Apr 12;126(3):803-10. Epub 2011 Jan 12.

Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd., Novato, CA 94945, USA.

View Article
April 2011

ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.

Cancer Res 2010 May 20;70(9):3709-17. Epub 2010 Apr 20.

Buck Institute for Age Research, Novato, California 94945, USA.

View Article
May 2010

Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California.

BMC Public Health 2010 Apr 30;10:228. Epub 2010 Apr 30.

County of Marin, Department of Health and Human Services, 20 North San Pedro Road, San Rafael, CA 94903, USA.

View Article
April 2010

Development of a highly stable and targetable nanoliposomal formulation of topotecan.

J Control Release 2010 Jan 15;141(1):13-21. Epub 2009 Aug 15.

Hermes Biosciences, Inc., 61 Airport Boulevard, Suite D, South San Francisco, CA 94080, USA.

View Article
January 2010

Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.

Cancer Chemother Pharmacol 2009 Sep 30;64(4):741-51. Epub 2009 Jan 30.

Hermes Biosciences Inc, South San Francisco, CA 94080, USA.

View Article
September 2009

Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.

Clin Cancer Res 2009 May 21;15(9):3163-71. Epub 2009 Apr 21.

Department of Laboratory Medicine, University of California, San Francisco, CA, USA.

View Article
May 2009

Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.

Breast Cancer Res 2008 17;10(4):R61. Epub 2008 Jul 17.

Buck Institute for Age Research, Redwood Boulevard, Novato, California 94945, USA.

View Article
April 2009

Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis.

Cancer Res 2009 Feb 3;69(4):1279-83. Epub 2009 Feb 3.

Department of Pathology, Comprehensive Cancer Center, and National Foundation for Cancer Research, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019, USA.

View Article
February 2009

Ageing, oxidative stress and cancer: paradigms in parallax.

Nat Rev Cancer 2008 Nov;8(11):875-9

Christopher C. Benz and Christina Yau are at the Buck Institute for Age Research, Novato, California 94945, USA.

View Article
November 2008

Unraveling the biologic and clinical complexities of HER2.

Clin Breast Cancer 2008 Oct;8(5):392-401

Comprehensive Cancer Center, University of California, San Francisco, CA 94115-1710, USA.

View Article
October 2008

Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.

Cancer Epidemiol Biomarkers Prev 2008 May 7;17(5):1028-33. Epub 2008 May 7.

Department of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, California, USA.

View Article
May 2008

Impact of aging on the biology of breast cancer.

Crit Rev Oncol Hematol 2008 Apr 18;66(1):65-74. Epub 2007 Oct 18.

Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA.

View Article
April 2008

Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.

Mol Cancer Ther 2007 Oct;6(10):2737-46

Department of Anesthesia, University of California at San Francisco, Room 3C38, 1001 Potrero Avenue, San Francisco, CA 94110, USA.

View Article
October 2007

Anti-oncomir suppression of tumor phenotypes.

Mol Interv 2007 Aug;7(4):199-202, 180

Department of Medicine, University of California, San Francisco, CA 94143, USA.

View Article
August 2007

Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.

Mol Pharmacol 2007 Jun 28;71(6):1525-34. Epub 2007 Mar 28.

Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd., Novato, CA 94945, USA.

View Article
June 2007

Meeting report: Translational Research at the Aging and Cancer Interface.

Cancer Res 2007 May;67(10):4560-3

Buck Institute for Age Research, Novato, California, USA.

View Article
May 2007

Quantification of cysteine oxidation in human estrogen receptor by mass spectrometry.

Anal Chem 2007 Apr 21;79(8):3083-90. Epub 2007 Mar 21.

Buck Institute for Age Research, Novato, California 94945, USA.

View Article
April 2007

Type and duration of exogenous hormone use affects breast cancer histology.

Ann Surg Oncol 2007 Feb 14;14(2):695-703. Epub 2006 Nov 14.

Department of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, California, 94602, USA.

View Article
February 2007

Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b.

J Biol Chem 2007 Jan 16;282(2):1479-86. Epub 2006 Nov 16.

Buck Institute for Age Research, Novato, California 94945, USA.

View Article
January 2007

Novel pathways associated with quinone-induced stress in breast cancer cells.

Drug Metab Rev 2006 ;38(4):601-13

Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, Novato, CA 94945, USA.

View Article
January 2007

Breast cancer growth prevention by statins.

Cancer Res 2006 Sep;66(17):8707-14

Department of Surgery, University of California San Francisco/Mt. Zion Medical Center, Room C342, 1600 Divisadero, San Francisco, CA 94115, USA.

View Article
September 2006

Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription.

Assay Drug Dev Technol 2006 Jun;4(3):273-84

Program of Cancer and Development Therapeutics, Buck Institute for Age Research, Novato, CA 94945, USA.

View Article
June 2006

Identification of an epithelial-specific enhancer regulating ESX expression.

Gene 2006 Feb 22;367:118-25. Epub 2005 Nov 22.

Cancer Research Institute, University of California San Francisco, Box 0808, San Francisco, CA 94143-0808, USA.

View Article
February 2006

Rapid alteration of microRNA levels by histone deacetylase inhibition.

Cancer Res 2006 Feb;66(3):1277-81

Program of Cancer and Developmental Therapeutics, Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA.

View Article
February 2006

Reactivity of zinc finger cysteines: chemical modifications within labile zinc fingers in estrogen receptor.

J Am Soc Mass Spectrom 2005 Dec 24;16(12):2017-26. Epub 2005 Oct 24.

Buck Institute for Age Research, Novato, CA 94945, USA.

View Article
December 2005

Vitamin K3 (menadione)-induced oncosis associated with keratin 8 phosphorylation and histone H3 arylation.

Mol Pharmacol 2005 Sep 6;68(3):606-15. Epub 2005 Jun 6.

Program of Cancer and Developmental Therapeutics, Buck Institute for Age Research, 8001 Red-wood Blvd., Novato, CA 94945, USA.

View Article
September 2005

Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.

Int J Biochem Cell Biol 2005 May;37(5):1130-44

Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd., Novato, CA 94945, USA.

View Article
May 2005

Clinical development of histone deacetylase inhibitors as anticancer agents.

Annu Rev Pharmacol Toxicol 2005 ;45:495-528

Hermes Biosciences, Inc., South San Francisco, California 94080, USA.

View Article
May 2005

Risk factors for estrogen receptor-positive breast cancer.

Arch Surg 2005 Jan;140(1):58-62

Department of Surgery, University of California, San Francisco, Cancer Center, 94115, USA.

View Article
January 2005

Future directions of liposome- and immunoliposome-based cancer therapeutics.

Semin Oncol 2004 Dec;31(6 Suppl 13):196-205

UCSF Comprehensive Cancer Center, San Francisco, CA 94115-1710, USA.

View Article
December 2004

Development of ligand-targeted liposomes for cancer therapy.

Expert Opin Ther Targets 2004 Aug;8(4):335-53

University of California at San Francisco, CA 94143, USA.

View Article
August 2004

Geographic excess of estrogen receptor-positive breast cancer.

Cancer Epidemiol Biomarkers Prev 2003 Dec;12(12):1523-7

Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, Novato, California 94945, USA.

View Article
December 2003

Essential cysteine-alkylation strategies to monitor structurally altered estrogen receptor as found in oxidant-stressed breast cancers.

Anal Biochem 2003 Sep;320(1):21-31

Buck Institute for Age Research (Program of Cancer and Developmental Therapeutics), Novato, CA 94945, USA.

View Article
September 2003

Age-dependent changes in breast cancer hormone receptors and oxidant stress markers.

Breast Cancer Res Treat 2002 Dec;76(3):221-36

Comprehensive Cancer Center, University of California, San Francisco, CA, USA.

View Article
December 2002

Age-associated biomarker profiles of human breast cancer.

Int J Biochem Cell Biol 2002 Nov;34(11):1318-30

Stiftung Tumorbank Basel and Department of Research, University Clinics, Basel, Switzerland.

View Article
November 2002

Redox control of zinc finger proteins.

Methods Enzymol 2002 ;353:54-69

Mass Spectrometry Facility, Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, USA.

View Article
August 2002

Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.

Biochim Biophys Acta 2002 Aug;1591(1-3):109-118

Department of Anesthesia and Pharmaceutical Chemistry, University of California-San Francisco, SF General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110, USA.

View Article
August 2002

ErbB2 activation of ESX gene expression.

Oncogene 2002 May;21(24):3934-8

Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA.

View Article
May 2002

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Clin Cancer Res 2002 Apr;8(4):1172-81

Division of Hematology/Oncology, University of California, San Francisco, San Francisco, California 94143, USA.

View Article
April 2002

Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen.

Mol Cancer Ther 2002 Apr;1(6):385-92

Program of Cancer and Development Therapeutics, Buck Institute for Age Research, Novato, California 94945, USA.

View Article
April 2002